Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Rosemary Gale, PhD, David C. Linch, Brian J.P Huntly, Elli Papaemmanuil, PhD, Paresh Vyas, Alan K. Burnett, MD, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 664.

https://doi.org/10.1182/blood-2018-99-116482

Published: 2018

Journal Articles

Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Alan K. Burnett, MD, Rosemary Gale, PhD, David C. Linch, Amanda Gilkes, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 1392.

https://doi.org/10.1182/blood-2018-99-116542

Published: 2018

Journal Articles

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Kate Stringaris, MD, MRCP, FRCPath, A. John Barrett, MD, Robert Hills, MA, MSc, DPhil, David C Linch, MD, FMedSci, Rosemary Gale, PhD, Christopher Allen, Paula Garland, MBBS, MRCP, Ruhena Sargent, Hugues de Lavallade, Abdullah Alsuliman, Ahmad Khoder, Dr, Ian H Gabriel, Dr, Takuya Sekine, Alan Burnett, Katayoun Rezvani, Jane F. Apperley

Blood (2010) 116 (21): 1697.

https://doi.org/10.1182/blood.V116.21.1697.1697

Published: 2010

Journal Articles

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Claire L Green, Catherine M Evans, Robert Hills, MA, MSc, DPhil, Lu Zhao, Alan Burnett, David C Linch, MD, Rosemary Gale, PhD

Blood (2010) 116 (21): 100.

https://doi.org/10.1182/blood.V116.21.100.100

Published: 2010

Journal Articles

Estimating the Replication Rate of Hematopoietic Stem Cells (HSC) In Vivo.

Janis L. Abkowitz, MD, Sandra N Catlin, PhD, Rosemary Gale, PhD, Lambert Busque, MD, Peter Guttorp, PhD

Blood (2009) 114 (22): 2522.

https://doi.org/10.1182/blood.V114.22.2522.2522

Published: 2009

Journal Articles

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

Carol Guy, Amanda Gilkes, Rosemary Gale, PhD, David C. Linch, FRCP, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP

Blood (2008) 112 (11): 2978.

https://doi.org/10.1182/blood.V112.11.2978.2978

Published: 2008

Journal Articles

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Marc R Mansour, MBChB, MRCP, Rosemary Gale, PhD, Asim Khwaja, Martin Pule, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP, David Linch

Blood (2008) 112 (11): 3364.

https://doi.org/10.1182/blood.V112.11.3364.3364

Published: 2008

Journal Articles

FLT3 ITD and TKD Mutations Differ in Their Functional Consequence in Both Cell Line Models and Primary Hematopoietic Cells

Adam J Mead, Asim Khwaja, Rosemary Gale, PhD, David C. Linch, FRCP

Blood (2008) 112 (11): 3791.

https://doi.org/10.1182/blood.V112.11.3791.3791

Published: 2008

Journal Articles

The Relationship Between Wild Type and Mutant-Positive Platelets in Essential Thrombocythemia Patients with a JAK2 V617F Mutation

Jonathan R Lambert, MRCP, Rosemary Gale, PhD, David C. Linch, FRCP

Blood (2008) 112 (11): 3728.

https://doi.org/10.1182/blood.V112.11.3728.3728

Published: 2008

Journal Articles

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Rosemary Gale, PhD, Robert Hills, MA, MSc, DPhil, Claire Green, Yashma Patel, Amanda Gilkes, Michelle Lazenby, Keith Wheatley, DPhil, David C. Linch, FRCP, Alan Burnett

Blood (2008) 112 (11): 554.

https://doi.org/10.1182/blood.V112.11.554.554

Published: 2008

NARROW

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Estimating the Replication Rate of Hematopoietic Stem Cells (HSC) In Vivo.

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

FLT3 ITD and TKD Mutations Differ in Their Functional Consequence in Both Cell Line Models and Primary Hematopoietic Cells

The Relationship Between Wild Type and Mutant-Positive Platelets in Essential Thrombocythemia Patients with a JAK2 V617F Mutation

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only